Orthofix Medical (NASDAQ:OFIX) Shares Gap Up Following Insider Buying Activity

Orthofix Medical Inc. (NASDAQ:OFIX) shares gapped up prior to trading on Friday after an insider bought additional shares in the company. The stock had previously closed at $13.17, but opened at $13.79. Orthofix Medical shares last traded at $13.4610, with a volume of 77,899 shares traded.

Specifically, major shareholder Engine Capital Management, Lp purchased 13,061 shares of the stock in a transaction on Wednesday, February 25th. The stock was purchased at an average price of $12.96 per share, for a total transaction of $169,270.56. Following the acquisition, the insider owned 3,673,092 shares in the company, valued at $47,603,272.32. This trade represents a 0.36% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Engine Capital Management, Lp acquired 124,797 shares of Orthofix Medical stock in a transaction dated Tuesday, February 24th. The stock was purchased at an average cost of $12.55 per share, for a total transaction of $1,566,202.35. Following the completion of the purchase, the insider owned 3,663,133 shares in the company, valued at approximately $45,972,319.15. The trade was a 3.53% increase in their position. The disclosure for this purchase is available in the SEC filing.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Orthofix Medical in a research note on Thursday, January 22nd. Barrington Research decreased their price target on Orthofix Medical from $18.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday. TD Cowen assumed coverage on Orthofix Medical in a research report on Tuesday, January 27th. They issued a “hold” rating and a $14.00 price objective for the company. Finally, Canaccord Genuity Group cut their target price on Orthofix Medical from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $18.25.

Trending Headlines about Orthofix Medical

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Engine Capital (a major shareholder) bought shares in two recent transactions — ~124,797 shares at ~$12.55 on Feb. 24 and an additional 13,061 shares at ~$12.96 on Feb. 25 — increasing its stake and signaling confidence from a large institutional holder. Engine Capital purchases OFIX shares
• Neutral Sentiment: Analysts trimmed price targets but kept several constructive ratings: Canaccord cut its target from $24 to $20 (still a “buy”) and others reduced targets modestly; consensus remains mixed (roughly a mid‑teens/$18-ish average target). This lowers upside expectations but does not indicate a broad teardown of the bull case. Analyst notes and price-target changes
• Negative Sentiment: Q4 results missed on EPS: reported ($0.06) vs. $0.44 expected; revenue was roughly in line but margins and ROE were negative — the EPS shortfall triggered investor selling and increased near-term skepticism. Shares down after earnings miss
• Negative Sentiment: Management flagged margin delays and issued revised 2026 guidance that shifts the narrative toward execution risk; until margin recovery and guidance clarity appear, the stock faces headwinds. Narrative shifting: margin delays and guidance

Orthofix Medical Stock Performance

The company has a market capitalization of $535.79 million, a price-to-earnings ratio of -5.78 and a beta of 0.78. The company has a 50 day moving average price of $14.08 and a 200 day moving average price of $14.70. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.38 and a current ratio of 2.45.

Orthofix Medical (NASDAQ:OFIX) last announced its quarterly earnings results on Tuesday, February 24th. The medical device company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.44 by ($0.50). Orthofix Medical had a negative return on equity of 20.38% and a negative net margin of 11.21%.The firm had revenue of $219.91 million during the quarter, compared to the consensus estimate of $218.72 million. Equities research analysts predict that Orthofix Medical Inc. will post -2.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Orthofix Medical

A number of large investors have recently modified their holdings of OFIX. CWM LLC grew its position in Orthofix Medical by 99.0% in the 3rd quarter. CWM LLC now owns 1,920 shares of the medical device company’s stock valued at $28,000 after purchasing an additional 955 shares during the period. Gabelli Funds LLC lifted its stake in shares of Orthofix Medical by 0.4% in the fourth quarter. Gabelli Funds LLC now owns 235,303 shares of the medical device company’s stock valued at $3,567,000 after buying an additional 1,000 shares in the last quarter. Raymond James Financial Inc. lifted its stake in shares of Orthofix Medical by 1.5% in the third quarter. Raymond James Financial Inc. now owns 66,812 shares of the medical device company’s stock valued at $978,000 after buying an additional 1,000 shares in the last quarter. Amundi grew its holdings in shares of Orthofix Medical by 2.7% during the fourth quarter. Amundi now owns 41,527 shares of the medical device company’s stock valued at $630,000 after buying an additional 1,086 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Orthofix Medical by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock worth $335,000 after acquiring an additional 1,213 shares in the last quarter. 89.76% of the stock is currently owned by institutional investors.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.